Torch

Dr Mark Wade

Lecturer in Genetics

Faculty and Department

  • Faculty of Health Sciences
  • Department of Biomedical Sciences

Qualifications

  • BSc (University of Nottingham)
  • MSc (Newcastle University)
  • PhD (Newcastle University)

Summary

I am a Lecturer in Genetics in the Department of Biomedical Sciences at the University of Hull where I lead the Cancer Epigenetics Team.

I was awarded my Ph.D. in 2012 having worked in the lab of Professor James Allan at Newcastle University studying the molecular genetics of radiation-induced breast cancer. I have continued my interest in this field and have current projects aiming to identify novel genomic biomarkers of radiation-induced cancer in collaboration with Professor Allan.

Prior to my current role I was a post-doctoral research associate in the lab of Dr Luke Gaughan from 2012-2017 studying the role of histone demethylase (HDMs) enzymes in breast cancer. In particular the function of the HDMs KDM4B and KDM3A and their role in estrogen receptor signalling.

My current research continues to investigate the role of epigenetic regulatory enzymes in cancer development and progression, particularly in breast cancer, in an aim to identify novel therapeutic targets. My current interests lie in 'epi-reader' proteins which recognise and interpret histone modifications in order to control gene expression.

Undergraduate

I am module coordinator for the Level 4 Principles of Genetics module and teach on the Level 5 Molecular Genetics and Proteomics module and Level 6 Human Genetics module. I also supervise undergraduate students for their Independent Research Projects at Level 6 and MSc by Thesis postrgraduate students and teach on the Level 4 and 5 skills modules.

Recent outputs

View more outputs

Journal Article

The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer

Jones, D., Wilson, L., Thomas, H., Gaughan, L., & Wade, M. (in press). The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer. Cancers, 11(8), https://doi.org/10.3390/cancers11081122

The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart

Onwuli, D. O., Samuel, S., Sfyri, P., Welham, K., Goddard, M., Abu-Omar, Y., …Beltran-Alvarez, P. (2019). The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart. International journal of cardiology, 282, 76-80. https://doi.org/10.1016/j.ijcard.2019.01.102

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition

Middleton, F. K., Patterson, M. J., Elstob, C. J., Fordham, S., Herriott, A., Wade, M. A., …Curtin, N. J. (2015). Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget, 6(32), https://doi.org/10.18632/oncotarget.6136

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer

Jones, D., Wade, M., Nakjang, S., Chaytor, L., Grey, J., Robson, C. N., & Gaughan, L. (2015). FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget, 6(30), 29782-29794. https://doi.org/10.18632/oncotarget.4927

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy

O’Neill, D., Jones, D., Wade, M., Grey, J., Nakjang, S., Guo, W., …Gaughan, L. (2015). Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget, 6(28), 26029-26040. https://doi.org/10.18632/oncotarget.4347

Research interests

My research interests are mainly focused on epigenetic mechanisms in cancer, in particular breast cancer and glioblastoma. I am interested in enzymes which regulate the chemical modification of histones to control chromatin structure and gene expression, and their potential as therapeutic targets to treat cancer.

I also have interests in the molecular genetics of radiation-induced cancer and the development of ex vivo microfluidic platforms as novel therapeutic target validation tools.

Postgraduate supervision

There are current opportunities for self-funded PhD students in the area of epigenetic regulation in breast cancer and glioblastoma.